Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Allergy Therapeutics plc    AGY   GB00B02LCQ05

ALLERGY THERAPEUTICS PLC

(AGY)
  Report
Delayed Quote. Delayed London Stock Exchange - 01/20 04:29:31 am
20.6 GBX   +3.00%
01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
AQ
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
PU
2020ALLERGY THERAPEUTICS : Notice of Meeting
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ALLERGY THERAPEUTICS : BLOCK LISTING SIX MONTHLY RETURN

07/02/2020 | 09:08am EST

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.

Name of applicant: ALLERGY THERAPEUTICS PLC

Name of scheme: Allergy Therapeutics plc 2013 Long Term Incentive Plan

Period of return

From: 11 July 2018

To: 1 July 2020

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: 10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017

Balance of unallotted securities under scheme(s) from previous return: 7,949,152

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for)

Less: Number of securities issued/allotted under scheme(s) during period: 1,117,188

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 6,831,964

Contact:

Tel: +44 (0) 1903 845 820

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY).

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ALLERGY THERAPEUTICS PLC
01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
AQ
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
PU
2020ALLERGY THERAPEUTICS : Notice of Meeting
PU
2020ALLERGY THERAPEUTICS :  Allergy Therapeutics plc Preliminary Results for the yea..
AQ
2020ALLERGY THERAPEUTICS : Block listing six monthly return
AQ
2020ALLERGY THERAPEUTICS : Trading Update
AQ
2020ALLERGY THERAPEUTICS : welcomes European Academy of Allergy and Clinical Immunol..
AQ
2020ALLERGY THERAPEUTICS : Half-year Report
PU
2019ALLERGY THERAPEUTICS : Allergy Therapeutics announces update to Grass MATA MPL p..
AQ
2019ALLERGY THERAPEUTICS : Result of Annual General Meeting
AQ
More news
Financials
Sales 2021 83,4 M 114 M 114 M
Net income 2021 -4,55 M -6,22 M -6,22 M
Net cash 2021 29,5 M 40,4 M 40,4 M
P/E ratio 2021 -30,0x
Yield 2021 -
Capitalization 128 M 175 M 175 M
EV / Sales 2021 1,18x
EV / Sales 2022 1,24x
Nbr of Employees -
Free-Float 13,8%
Chart ALLERGY THERAPEUTICS PLC
Duration : Period :
Allergy Therapeutics plc Technical Analysis Chart | AGY | GB00B02LCQ05 | MarketScreener
Technical analysis trends ALLERGY THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 50,00 GBX
Last Close Price 20,00 GBX
Spread / Highest target 250%
Spread / Average Target 150%
Spread / Lowest Target 75,0%
EPS Revisions
Managers and Directors
NameTitle
Manuel Llobet Chief Executive Officer & Executive Director
Peter Sinclair Jensen Non-Executive Chairman
Bev Lees Group Director-Operations
Nicolas Alexander Ulrich Wykeman Chief Financial Officer & Executive Director
Murray Skinner Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGY THERAPEUTICS PLC20.30%175
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160